Vaccinex Inc Stock Price, News & Analysis

Vaccinex announced promising findings from the SIGNAL Phase 2 Huntington’s Disease Trial presented by CEO Maurice Zauderer at the EHDN2021 meeting. The trial highlighted the cognitive benefits of the pepinemab antibody, especially in patients with moderately advanced HD. A pivotal Phase 3 trial is being planned, with ongoing discussions for potential development partners. The SIGNAL trial included 268 subjects and points towards treating cognitive impairments in HD, a currently incurable disease. The company aims to advance treatments for both HD and Alzheimer's disease.

Vaccinex, Inc. (Nasdaq: VCNX) reported Q2 2021 financial results, ending the period with $22.4 million in cash. The company has commenced two clinical studies: pepinemab as a monotherapy for Alzheimer’s disease and in combination with KEYTRUDA^® for metastatic head and neck cancer. Positive interim data from the Huntington’s disease program highlights cognitive improvements and treatment efficacy. Upcoming milestones include topline data from Alzheimer’s trials expected in late 2022/early 2023 and early data from head and neck cancer studies anticipated in late 2022.

Vaccinex, Inc. (Nasdaq: VCNX) announced that Elizabeth Evans, PhD, will chair a symposium and present a poster at the XV European Meeting on Glial Cells in Health and Disease, held virtually from July 5 to 9, 2021. The symposium focuses on targeting glial cell activation for neurodegenerative disease treatment. Dr. Evans will discuss the clinical evaluation of pepinemab, a SEMA4D blocking antibody for Huntington's Disease and its Phase 1b/2a trial in Alzheimer’s Disease. The poster presentation will detail findings from these clinical trials.

Vaccinex (Nasdaq: VCNX) announced the activation of clinical sites for two significant studies. They aim to enroll at least 40 patients in a Phase 1/2 Alzheimer’s study evaluating pepinemab and 65 patients in a Phase 2 study assessing pepinemab in combination with Merck’s KEYTRUDA for advanced head and neck squamous cell carcinoma. Notable support comes from the Alzheimer’s Drug Discovery Foundation. The studies will measure cognition, brain imaging, and various efficacy endpoints, crucial for developing new therapies in neurodegenerative diseases and cancer.

Vaccinex, Inc. (Nasdaq: VCNX) announced that CEO Dr. Maurice Zauderer will present at the 2021 Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 1 at 4:30 PM ET, focusing on advancements in Vaccinex's neurology programs targeting Huntington’s and Alzheimer’s diseases, and their collaboration with Merck for head and neck cancer immunotherapy using pepinemab and KEYTRUDA®. A live video webcast will be available on the Vaccinex website post-presentation.

Vaccinex, Inc. (VCNX) has initiated a Phase 2 study of pepinemab combined with KEYTRUDA® for advanced head and neck cancer. The company announced positive results from the CLASSICAL-Lung trial published in Clinical Cancer Research, showing pepinemab's clinical activity in non-small cell lung cancer. Financially, Vaccinex raised $32 million through an open sale market agreement. For Q1 2021, revenue reached $850,000, with R&D expenses of $5.5 million. The company plans to start a Phase 1/2a trial for Alzheimer’s disease by Q2 2021.

Vaccinex, Inc. (Nasdaq: VCNX) announced the publication of results from its CLASSICAL-Lung clinical trial, evaluating pepinemab in combination with BAVENCIO® for treating non-small cell lung cancer (NSCLC). The Phase 1b/2 trial demonstrated clinical activity and safety, with a disease control rate (DCR) of 81% among immunotherapy naïve patients and 59% among those resistant to prior therapies. The results indicate that pepinemab may enhance the efficacy of checkpoint inhibitors, especially in challenging cases including PD-L1 negative tumors. The full data set is published in Clinical Cancer Research.

Vaccinex, Inc. (Nasdaq: VCNX) reported top-line results from the SIGNAL Phase 2 study showing potential cognitive benefits of pepinemab in Huntington's disease. The company plans to initiate a Phase 1b/2 study of pepinemab with KEYTRUDA® for head and neck cancer and an Alzheimer’s trial in Q2 2021. In Q1 2021, Vaccinex raised $32 million through an open market sale agreement. Revenue increased to $625,000 in 2020, while R&D expenses decreased to $21.5 million. The company anticipates pivotal trial partnerships for Huntington’s disease and has significant funding for upcoming studies.

Vaccinex, Inc. (Nasdaq: VCNX) announced that CEO Dr. Maurice Zauderer will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, from 2:30 to 3:00 PM ET. The presentation will cover the company's innovative approach to treating cancer and neurodegenerative diseases by targeting SEMA4D. A live webcast will be available for interested investors and stakeholders. Vaccinex's lead drug candidate, pepinemab, aims to enhance immune responses against tumors while addressing chronic inflammation in the brain.